Literature DB >> 11096050

Genetic polymorphism in paraoxonase is a risk factor for childhood focal segmental glomerulosclerosis.

Y Frishberg1, H Toledano, R Becker-Cohen, E Feigin, D Halle.   

Abstract

Focal segmental glomerulosclerosis (FSGS) is an important cause of end-stage renal failure (ESRF) in children. Our previous studies have shown that Arab children in Israel have a worse prognosis compared with Jewish patients despite similar clinical presentation and management. Progression of proteinuric glomerular diseases has been associated with alterations in lipid metabolism, and similarities have been drawn between the mechanisms underlying atherosclerosis and glomerulosclerosis. Paraoxonase (PON) is a high-density lipoprotein (HDL)-associated enzyme involved in preventing the oxidation of low-density lipoprotein (LDL), and an association has been shown between two genetic polymorphisms in PON1 and the risk of coronary artery disease. The aim of this study was to determine the frequency of these genetic polymorphisms in PON1 in Arab and Jewish children with FSGS and to determine any association with severity of outcome. Forty-seven children (21 Arab and 26 Jewish) with biopsy-proven FSGS and 274 healthy controls of matching ethnic origin were studied. The glutamine (A)-192-arginine (B) and the methionine (M)-55-leucine (L) polymorphisms were analyzed. The frequency of the A allele was similar in patients and controls (0.68 versus 0.71), as was that of the L allele (0.63 versus 0.6). When subgroups were analyzed, the prevalence of the LL genotype in Arab patients was significantly greater than in Jewish patients (57.1% versus 26.9%, P: < 0.05) and Arab controls (57.1% versus 28.9%, P: < 0.03). A trend in association was found between homozygosity for the L allele and progression of renal disease in Arab children. Homozygosity for the L allele is a risk factor for developing FSGS in Arab children and may be associated with a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096050     DOI: 10.1053/ajkd.2000.19842

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Paraoxonase 1 192 and 55 polymorphisms in nephrotic children.

Authors:  Nese Karaaslan Biyikli; Harika Alpay; Nurdan Yildiz; Bedia Agachan; Arzu Ergen; Umit Zeybek; Nilufer Bozkurt; Turgay Ispir
Journal:  Pediatr Nephrol       Date:  2006-03-26       Impact factor: 3.714

2.  Paraoxonase, total antioxidant response, and peroxide levels in children with steroid-sensitive nephrotic syndrome.

Authors:  Aydin Ece; Yildiz Atamer; Fuat Gürkan; Mehmet Davutoğlu; Yüksel Koçyiğit; Murat Tutanç
Journal:  Pediatr Nephrol       Date:  2005-06-08       Impact factor: 3.714

3.  Genetical, histological, and clinical characteristics of IgA-negative mesangioproliferative glomerulopathy.

Authors:  Kazunori Owada; Hodaka Suzuki; Tetsuo Katoh; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2009-11-25       Impact factor: 2.801

4.  Evaluation of certain constituents of antioxidant defense in youth treated in the past for steroid-sensitive idiopathic nephrotic syndrome.

Authors:  Maria Hanna Kniazewska; Anna Karolina Obuchowicz; Tomasz Wielkoszyński; Joanna Zmudzińska-Kitczak; Katarzyna Urban; Lidia Hyla-Klekot
Journal:  Pediatr Nephrol       Date:  2009-07-28       Impact factor: 3.714

5.  A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis.

Authors:  Conxita Jacobs-Cachá; Natàlia Puig-Gay; Dominic Helm; Mandy Rettel; Joana Sellarès; Anna Meseguer; Mikhail M Savitski; Francesc J Moreso; Maria José Soler; Daniel Seron; Joan Lopez-Hellin
Journal:  Sci Rep       Date:  2020-01-24       Impact factor: 4.379

Review 6.  Paraoxonase 3: Structure and Its Role in Pathophysiology of Coronary Artery Disease.

Authors:  Kumari Priyanka; Surjit Singh; Kirandip Gill
Journal:  Biomolecules       Date:  2019-12-03

7.  Evaluation of paraoxonase activity in children with nephrotic syndrome.

Authors:  Mohammad Hashemi; Simin Sadeghi-Bojd; Mohsen Raeisi; Abdolkarim Moazeni-Roodi
Journal:  Nephrourol Mon       Date:  2013-11-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.